The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.
 
Paul Joseph Hampel
No Relationships to Disclose
 
Kari G. Chaffee
No Relationships to Disclose
 
Wei Ding
Research Funding - Merck (Inst)
 
Timothy Call
No Relationships to Disclose
 
Saad Kenderian
Consulting or Advisory Role - Torii Pharmaceutical
Research Funding - Humanigen; Lentigen; Tolero Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Novartis
 
Eli Muchtar
No Relationships to Disclose
 
Jose Francisco Leis
No Relationships to Disclose
 
Asher Alban Akmal Chanan-Khan
No Relationships to Disclose
 
Deborah Bowen
No Relationships to Disclose
 
Amie L. Fonder
No Relationships to Disclose
 
Susan M. Schwager
No Relationships to Disclose
 
Susan L. Slager
No Relationships to Disclose
 
Tait D. Shanafelt
Research Funding - Abbvie (Inst); Celgene (Inst); Cephalon (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Intellectual property EGCG in combination with chemotherapy owned by Mayo Clinic (Inst)
 
Neil E. Kay
Consulting or Advisory Role - Agios; Celgene; CytomX Therapeutics; Gilead Sciences; Infinity Pharmaceuticals; MorphoSys
Research Funding - Acerta Pharma; Pharmacyclics/Janssen; Tolero Pharmaceuticals
 
Sameer Ashok Parikh
Research Funding - Pharmacyclics (Inst)